Form 8-K - Current report:
SEC Accession No. 0001193125-24-191518
Filing Date
2024-08-01
Accepted
2024-08-01 16:11:31
Documents
18
Period of Report
2024-08-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d814773d8k.htm   iXBRL 8-K 29771
2 EX-1.1 d814773dex11.htm EX-1.1 210715
3 EX-5.1 d814773dex51.htm EX-5.1 9262
7 GRAPHIC g814773g0726220822644.jpg GRAPHIC 2977
8 GRAPHIC g814773g0726220823411.jpg GRAPHIC 6052
9 GRAPHIC g814773snap1.jpg GRAPHIC 3957
  Complete submission text file 0001193125-24-191518.txt   453958

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA aldx-20240801.xsd EX-101.SCH 2838
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20240801_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20240801_pre.xml EX-101.PRE 11253
20 EXTRACTED XBRL INSTANCE DOCUMENT d814773d8k_htm.xml XML 3642
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 241166774
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)